Aims: Non-steroidal anti-inflammatory drugs have been associated with increased risk of congestive heart failure (CHF). We aimed to assess the impact of treatment with etoricoxib or diclofenac on ...

Bayer’s AskBio unit has reported the first clinical data for its congestive heart failure gene therapy, showing preliminary signs of efficacy with no serious adverse events linked to the treatment.

Compared to those without heart failure, the rate of flu-related hospitalization was highest for patients with congestive heart failure followed by COPD and blood disorders, the data showed.

Bayer’s AskBio gene therapy unit has started recruiting patients into a phase 2 trial of its AB-1002 candidate for congestive heart failure (CHF), buoyed by encouraging data from a first-in ...

(Jan. 30 issue) 1 report the highly anticipated results of the SUMMIT trial, which compared tirzepatide with placebo in patients with heart failure with preserved ejection fraction and assessed ...